Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative solutions for people living with rare diseases, today announced the recipients of its "Find For Rare" research grant program. The independently assessed, expert-led research grant initiative aims to improve patient care and management by recognising innovative research in three lysosomal diseases: Fabry disease, alpha-mannosidosis, and cystinosis.
The selected projects demonstrated significant potential to address unmet needs within these rare communities. The recipients include:
- Fabry disease: Mitra Tavakoli, University of Exeter, Exeter, UK, for her project "FAB-PAIN: Precise phenotyping of neuropathy using a range of novel biomarkers in Fabry Disease”
- Project overview: This project aims to explore a range of novel biomarkers to better understand the pain pathways and its pathophysiology in Fabry disease. The findings may lead to the development of a range of new neuropathic biomarkers, advancing the understanding of disease mechanisms and facilitating the creation of diagnostic tools and therapeutic interventions.
- Alpha-mannosidosis: Margarita Dinamarca, University of Basel, Basel, Switzerland, for her project "Investigating brain endothelial dysfunction in alpha-mannosidosis"
- Project Overview: This research is significant for its dual contributions: unraveling the mechanisms by which alpha-mannosidosis disrupts endothelial cell function and pioneering a targeted therapeutic strategy using nanocarriers
- Cystinosis: Francesco Bellomo, Ospedale Pediatrico Bambino Gesù – IRCCS, Rome, Italy, for his project "Study of molecular mechanisms underlying the effects of ketogenic diet in cystinosis"
- Project Overview: This research project investigates the potential of a ketogenic diet to treat nephropathic cystinosis, a rare genetic disorder leading to kidney disease. By studying the diet's effects in murine models, significant reductions in symptoms such as Fanconi syndrome, inflammation, and fibrosis were observed. The project aims to develop an in vitro system to further explore the molecular mechanisms behind these benefits, potentially enabling the discovery of new therapeutic options.
Applications opened for submission on August 08, 2024, and a total of 82 applications from 23 countries were received. All submitted applications were evaluated by a steering committee of 10 independent leading experts in the field of Lysosomal Diseases, who received an honorarium for participating and reviewing the research projects. Details regarding the application criteria can be located here.
"Fabry disease, alpha-mannosidosis, and cystinosis are rare and ultra-rare lysosomal diseases causing severe, progressive, lifelong challenges, often complicated by diagnostic delays due to their complex and gradual progression," said Enrico Piccinini,Senior Vice President, EU and International, Rare Diseases at Chiesi Group. "Further research is vital for better diagnostics, new management options, and improved patient outcomes. The selection of these three projects through 'Find For Rare' highlights our deep commitment to advancing Lysosomal Diseases care by fostering crucial innovation to meet the evolving needs of patients and their families."
Chiesi hosted a ceremony on June 18, 2025, at Chiesi’s headquarters in Parma, Italy, to formally recognise the grant recipients and their innovative research.
“The quality and scientific rigor of the proposals submitted to Find For Rare this year were impressive. Each selected project stood out for its potential to address real, day-to-day challenges faced by patients and caregivers affected by lysosomal diseases,” said Prof. Christina Lampe, Chair of the Find For Rare Steering Committee. “By supporting research that is both innovative and patient-focused, this program helps accelerate the translation of science into meaningful impact for rare disease communities.”
About Find For Rare
The Find For Rare Research Grant Initiative has been designed to support original research projects that advance knowledge in the fields of Fabry disease, alpha-mannosidosis, and cystinosis. The categories of research eligible for funding are projects aimed at improving understanding of the factors affecting diseases, from pathogenesis to progression, and studies of patient tailored clinical management.
Research grants were provided to organisations operating in the health or scientific research sector. Proposals were welcome from all global regions other than the Americas, with application documents required to be in English.
About Lysosomal Diseases
Lysosomal Diseases are inborn errors of metabolism that are characterised by an abnormal build-up of substances in the body's cells as a result of enzyme deficiencies.1 The build-up of these substances can affect different parts of the body, including the skeleton, central nervous system (brain), lungs, heart, and eyes. Whilst there has been progress in clinical knowledge, more research in Lysosomal Diseases can be beneficial.1
About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system.
References |
1 NCBI. Lysosomal Storage Disease. Available at: https://www.ncbi.nlm.nih.gov/books/NBK563270/#:~:text=Lysosomal%20storage%20diseases%20(LSDs)%20are,to%20great%20morbidity%20and%20mortality. |
UK-CHI-2500657 June 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20250619863550/en/
Contacts
Chiesi Global Rare Diseases Media
Sky Striar
LifeSci Communications
sstriar@lifescicomms.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG Acquires a 49.87% Stake in Transportadora de Gas del Perú (TgP)19.12.2025 18:42:00 CET | Press Release
EIG, through its managed investment vehicles, acquired a 49.87% equity stake in Transportadora de Gas del Perú S.A. (“TgP”) from Canada Pension Plan Investment Board today. TgP operates Peru’s principal natural gas and natural gas liquids pipelines under a long-term concession, supplying approximately 40% of the country’s power generation. “We are delighted to complete this transaction and embark on the next chapter of our partnership with TgP,” said Matt Hartman, EIG’s Global Head of Infrastructure. “Our priority is to support TgP’s operational excellence and long-term stability, delivering value for customers and stakeholders throughout Peru.” About EIG EIG is a leading institutional investor in the global energy and infrastructure sectors with $24.3 billion assets under management as of September 30, 2025. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 43-year history, EIG has committed over $51.7 billion to the energ
Klarna Partners With Coinbase to Add Stablecoin to Funding Mix19.12.2025 18:00:00 CET | Press Release
Klarna, the global digital bank and flexible payments provider, has partnered with Coinbase to add stablecoin funding to its broad range of traditional sources of funding, which include consumer deposits, long-term loans and short-dated commercial paper. The digital bank plans to raise short-term funding from institutional investors denominated in USDC utilizing Coinbase’s digitally native infrastructure. Adding a USDC-denominated funding source enables Klarna to access USD-like funding directly, tapping into a new pool of institutional investors. “This is an exciting first step into a new way to raise funding,” said Niclas Neglén, Chief Financial Officer, Klarna, “Stablecoin connects us to an entirely new class of institutional investors, and gives us the potential to diversify our funding sources in ways that simply weren't possible a few years ago. This is just the beginning of how digital assets can work alongside our traditional funding sources." Klarna chose Coinbase for this ini
CyberArk Named a Leader in IDC MarketScape: Worldwide Integrated Solutions for Identity Security 202519.12.2025 17:00:00 CET | Press Release
CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that it has been recognized as a Leader in the IDC MarketScape: Worldwide Integrated Solutions for Identity Security 2025 Vendor Assessment. CyberArk extends dynamic privilege controls across all identity types with its unified platform, enabling organizations to improve efficiencies and streamline security operations. This IDC MarketScape report notes, “More change has occurred in the identity security marketplace in the past two years than in almost a decade. Vendors are entering a new phase defined by the emergence of intelligence technologies, none of which are specifically defined by any industry standards. Though different by design, the new adjacent IAM offerings are largely focused on improved vulnerability and threat management visibility and automated and predictive attack detection capabilities.” It also notes, “By addressing these evolving identity types within a unified framework, CyberArk enh
New York Liberty and Ant International’s Alipay+ Announce Multiyear Partnership Focused on Empowerment, Sustainability and Youth Development19.12.2025 14:30:00 CET | Press Release
The New York Liberty and Ant International’s Alipay+, a leading cross-border fintech services platform based in Singapore, today announced a multiyear partnership, making Alipay+ an Official Sponsor and Innovation Partner for Sustainability of the New York Liberty. Through this partnership, Alipay+ and the Liberty will jointly support community programs designed to advance community empowerment, environmental sustainability and youth development across New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219678825/en/ Peng Yang, CEO, Ant International and Clara Wu Tsai, Vice Chair, Brooklyn Sports and Entertainment; Governor, New York Liberty “Our partnership with Alipay+ goes beyond the game,” said Keia Clarke, Chief Executive Officer, New York Liberty. “Together, we are investing in the future of New York—its people, its environment, and its youth. Ant International’s commitment to community empowerment, sustai
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 14:00:00 CET | Press Release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too few carriers of the variant exist to draw statistically meaningful conclusions. As a result, even the most advanced models trained on observational datas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom